This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
by Zacks Equity Research
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
BIIBPositive Net Change BMYPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bear of the Day: Oscar Health (OSCR)
by Kevin Cook
Despite a big boost in revenue guidance, analysts reversed course on profitability for this digital insurer
OSCRNegative Net Change
insurance medical
Should You Buy or Sell CURLF Stock Amid Renewed Legalization Hopes?
by Sundeep Ganoria
Curaleaf's shares have soared over 200% on renewed legalization optimism, but domestic weakness and profit hurdles cloud the outlook.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CURLFNegative Net Change
marijuana medical
The Zacks Analyst Blog Tesla, UnitedHealth, Shopify and Waterstone Financial
by Zacks Equity Research
Tesla's robotaxi launch, UnitedHealth's cost challenges, and Shopify's AI-driven merchant tools headline Zacks' latest research roundup.
UNHNegative Net Change TSLANegative Net Change SHOPNegative Net Change WSBFNegative Net Change
auto-tires-trucks computers finance medical
Hologic Expands Panther Fusion's Menu With Diagnostic Innovation
by Moumi Mondal
HOLX expands its Panther Fusion platform with new GI bacterial assays, securing FDA and EU approvals to boost Diagnostics growth.
HOLXNegative Net Change MYGNPositive Net Change QGENNegative Net Change
medical medical-devices
Should You Continue to Hold Bio-Techne Stock in Your Portfolio?
by Zacks Equity Research
TECH drives growth via acquisitions, international strength and innovation. However, it faces macro pressures and rising competition.
CAHPositive Net Change MASINegative Net Change TECHNegative Net Change PAHCPositive Net Change
medical medical-devices
New Strong Sell Stocks for October 8th
by Zacks Equity Research
ACHC, AGL and BRLT have been added to the Zacks Rank #5 (Strong Sell) List on October 8, 2025.
AGLNegative Net Change ACHCNegative Net Change BRLTPositive Net Change
medical
Top Research Reports for Tesla, UnitedHealth & Shopify
by Mark Vickery
Tesla grapples with delivery declines and margin pressure but eyes its robotaxi launch and energy unit as potential growth engines.
CCLPositive Net Change UNHNegative Net Change ETRPositive Net Change TSLANegative Net Change LNGPositive Net Change SHOPNegative Net Change WSBFNegative Net Change
auto-tires-trucks computers finance medical
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
by Zacks Equity Research
AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
PFENo Net Change AMGNPositive Net Change GDRXNegative Net Change
biotechs medical pharmaceuticals
UnitedHealth Jumps 12% in a Month: But is it Healthy Enough to Buy?
by Kaibalya Pravo Dey
UNH surges 12% in a month, but with rising costs and regulatory pressures, is now the time to buy or wait?
UNHNegative Net Change BRK.BPositive Net Change HUMNegative Net Change ELVNegative Net Change
healthcare hmo insurance medical
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
by Zacks Equity Research
NYXH's first U.S. commercial use of its Genio system signals strong physician demand and sets the stage for broad adoption in sleep apnea care.
WSTNegative Net Change MEDPNegative Net Change NVSTPositive Net Change NYXHNegative Net Change
medical medical-devices
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
by Zacks Equity Research
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
NVONegative Net Change FOLDNo Net Change AVDLNegative Net Change SKYENegative Net Change
biotechnology biotechs medical pharmaceuticals
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
by Ahan Chakraborty
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
PFENo Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
by Zacks Equity Research
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
GSKPositive Net Change MRKNegative Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Alkermes Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ALKS stock based on the movements in the options market lately.
ALKSNegative Net Change
medical
Zacks.com featured highlights include Maximus, Pediatrix Medical, Sally Beauty and State Street
by Santanu Roy
Zacks highlights Maximus, Pediatrix Medical, Sally Beauty, and State Street as stocks trading near 52-week highs with potential for continued upside.
STTNegative Net Change SBHNegative Net Change MDNegative Net Change MMSNegative Net Change
business-services finance medical retail
Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock
by Zacks Equity Research
TMO joins AstraZeneca's BioVentureHub to boost R&D, innovation and life science access.
AZNPositive Net Change TMONegative Net Change MASINegative Net Change PAHCPositive Net Change
medical medical-devices
Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics
by Zacks Equity Research
Zacks highlights Amicus Therapeutics, Micron Technology, and General Dynamics as top picks with upgraded broker ratings and strong earnings outlooks.
GDPositive Net Change MUNegative Net Change FOLDNo Net Change
aerospace computers medical
Reasons to Add Omnicell Stock to Your Portfolio Right Now
by Zacks Equity Research
OMCL's expanding SaaS portfolio, overseas growth plans, and solid balance sheet position it for sustained momentum despite rising competition.
BSXPositive Net Change OMCLPositive Net Change MASINegative Net Change PAHCPositive Net Change
medical
CAH Expands Distribution Network With Indianapolis Facility
by Zacks Equity Research
Cardinal Health accelerates its multi-year supply chain transformation with a new flagship Indianapolis distribution center, reinforcing automation-driven efficiency while building on recent logistics expansions in Ohio and Texas.
CAHPositive Net Change MASINegative Net Change MMSIPositive Net Change WSTNegative Net Change
medical medical-devices
New Strong Buy Stocks for October 7th
by Zacks Equity Research
ALHC, STNE, EGAN, PAHC and MTG have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2025.
MTGPositive Net Change EGANPositive Net Change PAHCPositive Net Change STNENegative Net Change ALHCNegative Net Change
insurance medical
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
by Zacks Equity Research
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
AZNPositive Net Change PFENo Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
by Zacks Equity Research
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
RHHBYPositive Net Change JAZZPositive Net Change ETNBNo Net Change
biotechnology biotechs medical pharmaceuticals
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment
by Zacks Equity Research
IceCure Medical shares surge after FDA clears ProSense, marking the first minimally invasive breast cancer treatment for women aged 70 and above.
WSTNegative Net Change MEDPNegative Net Change NVSTPositive Net Change ICCMNegative Net Change
medical medical-devices
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
by Sundeep Ganoria
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
AZNPositive Net Change PFENo Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals